Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
5(62.5%)
Phase 2
3(37.5%)
8Total
N/A(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05152849Phase 2Completed

Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection

Role: lead

NCT04880187Phase 2Unknown

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Role: lead

NCT04816916Phase 2Terminated

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy

Role: lead

NCT04073407Not ApplicableTerminated

Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Role: lead

NCT04073368Not ApplicableCompleted

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Role: lead

NCT04134299Not ApplicableCompleted

To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease

Role: lead

NCT04147936Not ApplicableCompleted

Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

Role: lead

NCT03267745Not ApplicableCompleted

Effects of Amino Acid Formulation on Healthy Men Undergoing Unilateral Knee Immobilization

Role: collaborator

All 8 trials loaded